This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Ekta Bagri
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.
Sanofi (SNY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Sanofi (SNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings.
Sanofi (SNY) Stock Moves -0.45%: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $55.47, marking a -0.45% move from the previous day.
Zacks.com featured highlights include Unum, Graphic Packaging Holding, AutoNation and Sanofi
by Zacks Equity Research
Unum, Graphic Packaging Holding, AutoNation and Sanofi are part of the Zacks Screen of the Week article.
Will Sanofi (SNY) Surpass Estimates This Earnings Season?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.
Zacks.com featured highlights include Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil
by Zacks Equity Research
Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil are part of the Zacks Screen of the Week article.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like UNM, GPK, SNY and AN that are seeing price strength have a high chance of carrying the momentum forward.
Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce its workforce by approximately 60%.
FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine
by Zacks Equity Research
Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.
Zacks.com featured highlights include Sanofi, Medallion Financial, Plains All American Pipeline and KB Home
by Zacks Equity Research
Sanofi, Medallion Financial, Plains All American Pipeline and KB Home are part of the Zacks Screen of the Week article.
Pick These 5 Bargain Stocks With Amazingly Low EV/EBITDA Ratios
by Anindya Barman
We have screened bargain stocks UNM, SNY, KBH, PVH and VIV based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
3 Reasons Growth Investors Will Love Sanofi (SNY)
by Zacks Equity Research
Sanofi (SNY) possesses solid growth attributes, which could help it handily outperform the market.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Is Innoviva (INVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter
4 Low Price-to-Sales Stocks to Get the Best of the Market
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, MFIN, PAA and KBH hold promise.
AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms
by Zacks Equity Research
AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $54.18, marking a -0.44% move from the previous day.
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $53.22 in the latest trading session, marking a +1.16% move from the prior day.
The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly
by Zacks Equity Research
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.